DarshanTalks Podcast

Send us Fan Mail

Is your marketing team building a brand or a federal case? 
In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What looked like a runaway success story in the wound care space was actually a systematic violation of the False Claims Act. We break down the three fatal mistakes that led to 15-year prison sentences for executives: prioritizing reimbursement over medical necessity, incentivizing volume over value, and treating compliance as an afterthought. If you are an executive in biopharma or med-tech, this is a mandatory masterclass in where "aggressive growth" ends and criminal exposure begins. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providing "black box" recommendations that a clinician can’t independently verify in seconds, you aren't just drifting into a regulatory gray area, you’re likely standing outside the "safe zone."

In this episode, we break down the high-stakes intersection of FDA transparency, OIG inducement analysis, and the reality of clinical workflows.

In this episode, we cover:

• The 2026 FDA Update: Why "independence" is the new metric for non-device CDS.
• The Transparency Test: If a physician has to call your engineering team to explain a recommendation, you've already lost.
• OIG & The Anti-Kickback Statute: How "nudging" prescribing behavior creates massive financial liability, regardless of what you call your software.
• Automation Bias: How "fast and confident" AI leads to clinician reliance that regulators now view as a red flag.
• The FTC Factor: Why vague disclosures and hidden logic are no longer defensible under consumer protection standards.

Key Takeaway:

Regulators don't care if the tech works; they care if the compliance story holds up. If you cannot prove your recommendations are separated from commercial influence and fully explainable, you are exposed.

Are you ready to defend your AI? Don't wait for an investigator to walk through your door.

Subscribe to the KLF Deep Dive Podcast & Newsletter to navigate these risks before they turn into enforcement problems.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Darshan Kulkarni exposes a massive legal shift that is quietly dismantling the "Practice of Medicine" defense. We track the whiplash from the 2021 Ivermectin court victories to the DOJ’s aggressive 2025 memorandum targeting gender-affirming care.

Is "Intended Use" being weaponized as a high-tech surveillance tool? If the government can criminalize the intent behind a legal hormone, what does that mean for every manufacturer and physician operating in the off-label space? Darshan breaks down the April 2025 DOJ Memo and why your compliance strategy is likely outdated. This isn't just a policy change; it’s a precedent that puts every drug in the market at risk.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In this episode of the KLF Deep Dive, Darshan Kulkarni sits down with Phyllis Marcus, Vice President of the National Advertising Division (NAD) and former FTC veteran. They unpack the complex "grey area" where healthcare professional (HCP) communications bleed into the public consumer space. Phyllis reveals why labeling an ad "For Healthcare Professionals Only" may no longer protect a company from regulatory scrutiny and explains the NAD’s role as an independent adjudicator in high-stakes pharmaceutical disputes. If you are navigating the intersection of FDA, FTC, and NAD jurisdictions, this masterclass in advertising law is essential listening. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

State governments are racing to innovate by allowing AI to renew and improve prescriptions—but are they walking into a federal trap? In this episode of KLF Deep Dive, Darshan Kulkarni breaks down the "Utah Sandbox" model and the three massive warning signs flashing for the life sciences industry. From misdiagnosis risks to the nightmare of liability ownership, we explore why "innovation" doesn't grant immunity from federal law or malpractice lawsuits. If you are a healthcare executive or legal professional, this is the regulatory reality check you can't afford to miss. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In the high-stakes world of Life Science M&A, hiring expert consultants for GXP, IT, and data privacy is standard operating procedure. But there is a hidden structural flaw in most due diligence programs: Scope Creep. When a consultant identifies "high risk" in a data transfer mechanism, they aren't just giving a business metric—they are venturing into legal opinion. Without the protection of attorney-client privilege, these "compliance scorecards" and "heat maps" are discoverable goldmines for post-acquisition lawsuits and regulatory actions.

In this episode of KLF Deep Dive, we break down why all diligence must be commissioned and controlled through legal counsel. Learn how to transform operational findings into binding indemnities and ensure your next acquisition doesn't become your next legal nightmare.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 The NIH just dropped a regulatory bombshell: Notice NOT-OD-26-032. Effectively immediately, Basic Experimental Studies in Humans (BESH) are no longer classified as "Clinical Trials" for reporting purposes. Is this a victory for common sense, or an administrative "fudge" to hide years of academic non-compliance? In this episode, Darshan Kulkarni breaks down why this "Great Reset" changes the mathematics of due diligence, tech transfer, and company valuations. If you are licensing university tech, your "human clinical data" might have just been downgraded to "well-funded experiment." 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode of KLF Deep Dive, we examine a chilling shift in regulatory enforcement: the weaponization of "Intended Use." If the science hasn't changed and the law hasn't changed, why is the FDA pivoting from "advice-giving" to "subpoena-swinging"?

Host Darshan Kulkarni breaks down the legal whiplash between the Ivermectin era and the current crackdown on gender-affirming care. We explore why the "Practice of Medicine" shield is disappearing and what this "Rule of the Mood" means for pharmaceutical executives trying to navigate an increasingly political landscape. This is about the survival of the rule of law in life sciences.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Darshan Kulkarni dives into the terrifying reality of compliance failures at clinical trial sites. While most directors worry about standard fines, the true danger lies in the "off-the-book" penalties and the looming threat of criminal prosecution for employing excluded physicians. If you aren't auditing your lists correctly, you aren't just risking a citation—you're risking your entire career. 

Support the show

www.kulkarnilawfirm.com